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published Canadian literature. Deterministic and probabilistic sensitivity analyses 
were performed. Results: Mirabegron 50mg dominated tolterodine ER 4mg: incre-
mental cost savings were CA$118.91 (MOH perspective) and CA$140.48 (societal); and 
0.005 QALYs (MoH and societal) were gained. ICERs were robust over a wide range 
of sensitivity analyses, but were most sensitive to micturition symptom levels for 
tolterodine and to costs of subsequent therapy. ConClusions: Treatment with 
mirabegron 50mg is cost-effective compared with tolterodine ER 4mg in a population 
previously treated for OAB from Canadian health care and societal perspectives.
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objeCtives: The prevalence of prostate cancer in the Chinese population with 
abnormal prostate-specific antigen (PSA) levels of 4.0-10.0 ng/ml is low. The diag-
nosis can only rely on transrectal ultrasound-guided prostate biopsies (TRUS-Bx) 
which may cause major complications. We assess the cost-effectiveness of two 
diagnostic strategies for prostate cancer detection in Chinese men with abnormal 
PSA levels of 4.0-10.0 ng/ml and normal digital rectal examination of prostate 
(DRE). Methods: Using a decision tree model, we performed a cost-effectiveness 
analysis to compare the two strategies: 1) direct prostate biopsies (TRUS-Bx) and 
2) percent free PSA testing prior to TRUS-Bx. A systematic review of 855 patients 
with PSA levels of 4.0-10.0 ng/ml and normal DRE enrolled in a single medical 
institute from Jan 2002 to December 2005 was conducted. The outcome measures 
were the incremental cost-effectiveness ratio, and costs were calculated through 
activity-accumulation costing based on National Insurance Scheme Bill Size. A 
one-way sensitivity analysis was undertaken. The effectiveness was measured by 
means of the number of detected cases and actual cases (detected cases minus 
lost cases). A threshold analysis is used to illustrate the value of a given variable 
of which the two strategies have equal outcomes or costs. Results: The strat-
egy of percent free PSA with TRUS-Bx was dominant and found to be the most 
cost-effective. The incremental cost-effectiveness ratio for free PSA + TRUS-Bx 
compared with TRUS-Bx was USD 3,871.58. Strategy 2 (TRUS-Bx) would be more 
cost-effective if the cost of percent free PSA increased to USD 36.78 or if prostate 
cancer prevalence increased to 42%. ConClusions: The use of percent free PSA 
prior to TRUS-Bx is the most cost-effective diagnostic strategy and will become 
more cost-effective as prostate cancer prevalence increases in the ageing popula-
tion and the free PSA test costs down.
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objeCtives: To evaluate the cost-effectiveness of extracorporeal lithotripsy against 
ureteroscopic laser in the treatment of ureteral stones in the La Fe Hospital in 
Valencia. Methods: A decision tree was performed to evaluate the costs and 
effectiveness of two treatment strategies (starting with ESWL and second line URS, 
versus directly start with URS). It was considered as a parameter of effectiveness, 
the ratio of patient with stone-free status or the presence of insignificant residual 
fragments (< 3 mm) at 3 month of follow up. Subsequently, to consolidate the results 
of the decision tree, a sensitivity analysis of Monte Carlo with 1000 iterations was 
developed. Were available from a database of 162 patients treated for ureteral stones 
at the Hospital La Fe de Valencia. Of these, 77 were treated in lithotripsy sessions 
(27 % of whom had upper stones 1 cm), while 85 were referred directly to URS (the 
percentage of these patients with upper stones centimeter was 32.4 %). The unit 
cost of each treatment was calculated from data provided by the economic manage-
ment Department of Hospital La Fe and were 286.06 for each session in the case of 
ESWL and 1409.89 for URS. Results: The overall effectiveness after four sessions 
of lithotripsy plus second line URS was 99,76%, while in the case of URS was 98.81%. 
The average cost of ESWL plus URS alternative was 881.59 euros, while in the case 
of the strategy of starting with URS was 1,496 euros. Therefore, the ESWL plus URS 
showed dominant versus first line URS. For both group upper and less than 1 cm also 
ESWL plus URS was dominant. ConClusions: Thus, the combination of first line 
lithotripsy plus second line ureteroscopic laser is better than first line ureteroscopic 
laser for treatment of ureteral calculi in terms of in terms of cost effectiveness.
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objeCtives: To perform a cost-effectiveness analysis of Mycophenolate Sodium 
(MPS) vs Mycophenolate Mofetil (MMF) with empirical treatment of rejection, both 
options available at IMSS*. Methods: A Decision Model was designed to analyze 
effectiveness and treatment cost of MPS and MMF for renal transplant patients. 
The outcome was renal graft survival related to gastrointestinal tolerance in the 
first year. The model starts with a renal transplant performed, in a period of three 
months the patient may experience gastric intolerance or tolerance. For the patients 
showing gastric intolerance, there are two alternatives: switching to azathioprine 
or reducing the dose of mycophenolates (MPS or MMF). Then, the patient moves to 
the next state which may be rejection (humoral or cellular) or not. The absorbent 
state is the graft losses which include the cost of the intervention of renal trans-
plant plus the cost of replacement therapy: Ambulatory Peritoneal Dialysis (APD), 
Intermittent Peritoneal Mechanical Dialysis (IPMED), Intermittent Peritoneal Manual 
Dialysis (IPMAD) and Hemodialysis. A probabilistic sensitivity analysis (PSA) was 
objeCtives: Conduct an economic evaluation of darbepoetin alfa for the treatment 
of anaemia due to chronic kidney disease (CKD) compared to other erythropoiesis 
stimulating agents (ESAs) in patients on haemodialysis (HD) or peritoneal dialysis 
(PD) in Greece. Methods: A decision tree model was developed to compare overall 
costs per patient in control of darbepoetin alfa to other ESAs under different hae-
moglobin (Hb) concentrations and CKD patients. It estimates the economic impact 
of treating CKD patients on dialysis with darbepoetin alfa, originator and biosimi-
lar short-acting ESAs and pegylated epoetin beta to different Hb target strategies, 
10 (±1) g/dL and 11 (±1) g/dL, over 1 year. The effectiveness of “% patients under 
anaemia control” was defined as the number of patients being alive, not hospital-
ized, nor transfused during the analysis period. Clinical inputs depend on Hb target 
strategy and not on ESAs as extracted from published studies. Cost inputs are drug 
acquisition, administration and clinical event costs, the last comprising hospi-
talisation and blood transfusion costs (2014). Analysis was conducted from public 
third-party-payer perspective. Results: For both Hb target strategies in patients 
on HD or PD, darbepoetin alfa demonstrated the lowest overall costs per patient in 
control followed by short-acting originator ESAs, whereas pegylated epoetin beta 
and short-acting biosimilar ESAs showed the highest overall costs per patient in 
control. As clinical event costs are identical across all ESAs, the overall costs per 
patient in control are mainly affected by drug acquisition costs and by ESAs doses. 
Treatment with darbepoetin alfa at Hb target 11 (±1) g/dL is associated with the 
lowest overall costs per patient in control at € 8,210 and € 6,689, for patients on HD 
or PD, respectively. ConClusions: Darbepoetin alfa may be the most cost sav-
ing treatment compared to other ESAs for the management of anaemia (CKD) in 
patients on HD or PD in Greece.
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objeCtives: To evaluate the cost effectiveness of solifenacin 5mg compared with 
other oral antimuscarinic agents in adults with OAB from a UK NHS payer perspec-
tive. Methods: A Markov model was developed to model major symptoms of OAB 
and the efficacy and tolerability of antimuscarinics. A 5-year time-horizon with 
monthly cycles was used in the base case. Five levels of symptom severity were 
used for micturitions and incontinence (total: 25 health states). Treatment with at 
least two antimuscarinic agents was assumed before patients received botulinum 
toxin. For each antimuscarinic, there was a probability of continuing or discon-
tinuing medication, or switching to an alternative antimuscarinic with or without 
adverse events. Efficacy and tolerability inputs were based on a phase 3 study of 
solifenacin (Chapple et al. BJU Int 2004; 93: 303–10) and a mixed treatment com-
parison (results reported separately). Other model inputs were determined from the 
literature or expert opinion. All costs were based on GBP 2012/2013. Utilities were 
based on EuroQol-5D. Incremental cost-effectiveness ratios (ICER) were expressed 
as cost/quality-adjusted life year (QALY). Deterministic (DSA) and probabilistic 
(PSA) sensitivity analyses were performed. Results: Solifenacin 5mg was domi-
nant versus tolterodine extended-release 4mg, darifenacin 7.5mg, fesoterodine 4mg 
and solifenacin 10mg, and cost-effective versus darifenacin 15mg (ICER= £982.89/
QALY), fesoterodine 8mg (ICER= £232.53/QALY), oxybutynin extended-release 10mg 
(ICER= £1117.32/QALY) and trospium 60mg (ICER= £3674.25/QALY). Both DSA and PSA 
showed that results were robust at a willingness-to-pay threshold of £20,000/QALY. 
At a cost-effectiveness threshold of £20,000/QALY, the probabilities that solifena-
cin 5mg was cost-effective versus comparators were: 95.4% (tolterodine extended-
release 4mg), 92.1% (solifenacin 10mg), 97.3% (fesoterodine 4mg), 99.6% (fesoterodine 
8mg), 99.4% (oxybutynin extended-release 10mg), 99.4% (darifenacin 7.5mg), 99.2% 
(darifenacin 15mg), and 97.3% (trospium 60mg). ConClusions: Solifenacin 5mg 
appears to be a cost-effective strategy compared with other oral antimuscarinic 
agents for the treatment of adults with OAB from a UK NHS perspective.
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objeCtives: Mirabegron, a β 3-adrenoceptor agonist approved for the treatment of 
overactive bladder (OAB), has been shown to reduce OAB symptoms and improve 
HRQoL relative to placebo and to cause a lower incidence of dry mouth than tolter-
odine. We investigated the cost-effectiveness of mirabegron 50mg compared to 
tolterodine ER 4mg. Methods: A Markov model was developed to simulate man-
agement, symptom changes (micturitions, incontinence), and adverse events in OAB 
patients. The model predicted costs and QALYs over 1 year in a hypothetical cohort 
of Canadian patients previously treated for OAB. The analysis compared treatment 
with mirabegron 50mg to tolterodine ER 4mg, administered in a reference arm in 
the pivotal study SCORPIO and one of the antimuscarinic options most widely pre-
scribed and funded in Canada for the treatment of OAB, from both a payer (Ontario 
Ministry of Health and Long-term Care [MOH]) and societal perspective. Clinical and 
health state utility data for the model were based on the previously treated OAB 
population of SCORPIO. Transition probabilities between symptom severities were 
obtained using multinomial logistic regression models estimated from SCORPIO. 
Probabilities of discontinuation and switching therapy were derived from the litera-
ture. Resource utilisation estimates were based on clinical trial data, the literature 
and expert opinion. Unit costs were derived from official schedules for Ontario and 
